Budzik Michał P, Sobieraj Maciej T, Sobol Maria, Patera Janusz, Czerw Aleksandra, Deptała Andrzej, Badowska-Kozakiewicz Anna M
Department of Cancer Prevention, Medical University of Warsaw, Warsaw, Poland.
Public Central Teaching Clinical Hospital, Warsaw, Poland.
Arch Med Sci. 2019 Jul 17;18(2):432-439. doi: 10.5114/aoms.2019.86763. eCollection 2022.
Medullary breast cancer (MdBC) is an uncommon type of breast cancer representing 1-7% of all cases. It is characterized by the occurrence of many histopathological features associated with a high grade of malignancy.
Twelve MdBCs chosen from a group of 1,122 women suffering from invasive breast cancer were analyzed. Histopathological examination and analysis of a basic molecular profile, i.e. estrogen (ER), progesterone (PR) and HER2 receptor expression, and their comparison with invasive ductal breast cancer (IDC), were performed.
MdBC accounted for 1.07% of all analyzed invasive breast cancer patients. All patients were female, with an average age of 58.54 years. The MdBC group exhibited a larger median tumor diameter (2.05 vs. 1.89 cm), although ≥ T2 tumors comprised 42% vs. 51% for IDCs. Women without regional lymph node involvement (pN0) (83%) formed the largest group. There was a statistically significant difference in the presence of nodal involvement between the studied groups ( < 0.001). Based on the histological grade of malignancy, the majority of MdBC comprised grade II tumors (G2) (93%). In general, MdBC showed statistically higher histologic grade (G1-G3) than IDC ( = 0.003). The 5-year overall survival rate of MdBC patients was 91%. Most MdBCs (92%) were triple-negative, whereas the remaining 8% were HER2 positive.
MdBC presented at a younger age than IDC, had a higher histological grade, larger median size and less frequent regional lymph node involvement. Most MdBCs were triple-negative, whereas IDCs were predominantly luminal. Despite numerous aggressive pathological features of MdBC, its clinical outcome and overall prognosis are favorable.
髓样乳腺癌(MdBC)是一种罕见的乳腺癌类型,占所有病例的1%-7%。其特征是出现许多与高度恶性相关的组织病理学特征。
从1122例浸润性乳腺癌女性患者中选取12例MdBC进行分析。进行了组织病理学检查以及雌激素(ER)、孕激素(PR)和HER2受体表达等基本分子特征分析,并将其与浸润性导管癌(IDC)进行比较。
MdBC占所有分析的浸润性乳腺癌患者的1.07%。所有患者均为女性,平均年龄58.54岁。MdBC组肿瘤中位直径较大(2.05 vs. 1.89 cm),尽管≥T2肿瘤在MdBC组中占42%,而在IDC组中占51%。无区域淋巴结转移(pN0)的女性(83%)构成最大群体。研究组之间在淋巴结转移情况上存在统计学显著差异(<0.001)。根据恶性组织学分级,大多数MdBC为Ⅱ级肿瘤(G2)(93%)。总体而言,MdBC的组织学分级(G1-G3)在统计学上高于IDC(=0.003)。MdBC患者的5年总生存率为91%。大多数MdBC(92%)为三阴性,其余8%为HER2阳性。
MdBC比IDC发病年龄更年轻,组织学分级更高,中位肿瘤大小更大,区域淋巴结转移较少见。大多数MdBC为三阴性,而IDC主要为管腔型。尽管MdBC有许多侵袭性病理特征,但其临床结局和总体预后良好。